Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

F, Ma; Q, Ouyang; W, Li; Z, Jiang; Z, Tong; Y, Liu; H, Li; S, Yu; J, Feng; S, Wang; X, Hu; J, Zou; X, Zhu; B, Xu

doi:10.1200/jco.19.00108

Public

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Shared by NobleBlocks on Aug 20, 2019 • 12:00 AM UTC

Authors:

Ma F

Ouyang Q

Li W

Abstract

<h4>Purpose</h4>Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth fact...

Discussions